Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | NAAA | Q02083 | 2/20 | 0.58 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13577932 | 0.95 | MLYCD (0.73) | MLYCDL3MBTL1SMN1; SMN2EPHX2NAAA | |
| SCHEMBL28929298 | 0.94 | MLYCD (0.76) | MLYCDL3MBTL1SMN1; SMN2EPHX2NAAA | |
| SCHEMBL6358316 | 0.90 | ALDH1A1 (0.69) | MLYCDEPHX2TMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL28326194 | 0.88 | L3MBTL1 (0.73) | MLYCDL3MBTL1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL13577906 | 0.85 | MLYCD (0.73) | MLYCDL3MBTL1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL20892692 | 0.85 | RHOC (0.60) | MLYCDSMN1; SMN2NAAAALDH1A1HTT | |
| SCHEMBL1853826 | 0.85 | MLYCD (0.64) | MLYCDL3MBTL1SMN1; SMN2EPHX2NAAA | |
| SCHEMBL3580293 | 0.85 | SMN1; SMN2 (0.74) | MLYCDL3MBTL1SMN1; SMN2NAAATMEM97 | |
| SCHEMBL7975942 | 0.85 | EPHX2 (0.59) | MLYCDEPHX2TMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL19291293 | 0.84 | LDLR (0.53) | MLYCDL3MBTL1SMN1; SMN2EPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221369-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX, LLC (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2014121036-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX, LLC (US) | 2014-08-07 | — | — | WO | disclosed |
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| EP-1022272-B1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | SANKYO CO (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-6432993-B1 | BENZIMIDAZOLE OR IMIDAZO(4,5-B)PYRIDINE DERIVATES; IMMUNOMODULATORS; ALDOSE REDUCTASE AND LIPOXYGENASE INHIBITORS; DIABETES; PREVENTS LIPID PEROXIDATION; ANTILIPEMIC, HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-08-13 | — | — | US | disclosed |
| EP-1022272-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | CHRM3, CHRM2, CHRM1 | MLYCD 3946/4885L3MBTL1 3806/4885SMN1; SMN2 3865/4885 |
| US-20140221369-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SRD5A2, PPARD, SRD5A1 | MLYCD 793/4885L3MBTL1 3954/4885SMN1; SMN2 2291/4885 |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | CHRM3, CHRM2, CHRM1 | MLYCD 3946/4885L3MBTL1 3806/4885SMN1; SMN2 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.